Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features

Jennifer G. Goldman, Howard Andrews, Amy Amara, Anna Naito, Roy N. Alcalay, Leslie M. Shaw, Peggy Taylor, Tao Xie, Paul Tuite, Claire Henchcliffe, Penelope (Penny) Hogarth, Samuel Frank, Marie Helene Saint-Hilaire, Mark Frasier, Vanessa Arnedo, Alyssa N. Reimer, Margaret Sutherland, Christine Swanson-Fischer, Katrina Gwinn, Un Jung Kang

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objective: Examine relationships among neurodegenerative biomarkers and PD motor and nonmotor symptoms. Background: CSF alpha-synuclein is decreased in PD versus healthy controls, but whether plasma and saliva alpha-synuclein differentiate these groups is controversial. Correlations of alpha-synuclein among biofluids (CSF, plasma, saliva) or biomarkers (eg, beta-amyloid, tau [total, phosphorylated]) are not fully understood. The relationships of these biomarkers with PD clinical features remain unclear. Methods: BioFIND, a cross-sectional, observational study, examines clinical and biomarker characteristics in moderate-advanced PD and matched healthy controls. We compared alpha-synuclein concentrations across diagnosis, biofluids, and CSF biomarkers. Correlations of CSF biomarkers and MDS-UPDRS, motor phenotype, MoCA, and rapid eye movement sleep behavior disorder questionnaire scores in PD were examined. Results: CSF alpha-synuclein was lower in PD versus controls (P=.01), controlling for age, gender, and education. Plasma and saliva alpha-synuclein did not differ between PD and controls, and alpha-synuclein did not significantly correlate among biofluids. CSF beta-amyloid1-42 was lower in PD versus controls (P<.01), and correlated weakly with MoCA recall scores (r=0.23, P=.02). CSF alpha-synuclein was lower in the postural instability/gait difficulty phenotype than other motor phenotypes (P<.01). No CSF biomarkers predicted or correlated with total motor or rapid eye movement sleep behavior disorder scores. CSF alpha-synuclein correlated with beta-amyloid1-42, total-tau, and phosphorylated-tau (r=0.41, 0.81, 0.43, respectively; Ps<.001). Conclusion: Lower CSF alpha-synuclein is associated with diagnosis and motor phenotype in moderate-advanced PD. Plasma and saliva alpha-synuclein neither correlate with CSF alpha-synuclein, nor distinguish PD from controls. CSF beta-amyloid1-42 remains a potential biomarker for cognitive impairment in PD.

Original languageEnglish (US)
JournalMovement Disorders
DOIs
StateAccepted/In press - Jan 1 2017

Fingerprint

alpha-Synuclein
Saliva
Parkinson Disease
Cerebrospinal Fluid
Biomarkers
REM Sleep Behavior Disorder
Phenotype
Gait
Amyloid
Observational Studies
Cross-Sectional Studies

Keywords

  • Alpha-synuclein
  • Amyloid
  • Cerebrospinal fluid
  • Postural instability gait difficulty
  • Tau

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Goldman, J. G., Andrews, H., Amara, A., Naito, A., Alcalay, R. N., Shaw, L. M., ... Kang, U. J. (Accepted/In press). Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Movement Disorders. https://doi.org/10.1002/mds.27232

Cerebrospinal fluid, plasma, and saliva in the BioFIND study : Relationships among biomarkers and Parkinson's disease Features. / Goldman, Jennifer G.; Andrews, Howard; Amara, Amy; Naito, Anna; Alcalay, Roy N.; Shaw, Leslie M.; Taylor, Peggy; Xie, Tao; Tuite, Paul; Henchcliffe, Claire; Hogarth, Penelope (Penny); Frank, Samuel; Saint-Hilaire, Marie Helene; Frasier, Mark; Arnedo, Vanessa; Reimer, Alyssa N.; Sutherland, Margaret; Swanson-Fischer, Christine; Gwinn, Katrina; Kang, Un Jung.

In: Movement Disorders, 01.01.2017.

Research output: Contribution to journalArticle

Goldman, JG, Andrews, H, Amara, A, Naito, A, Alcalay, RN, Shaw, LM, Taylor, P, Xie, T, Tuite, P, Henchcliffe, C, Hogarth, PP, Frank, S, Saint-Hilaire, MH, Frasier, M, Arnedo, V, Reimer, AN, Sutherland, M, Swanson-Fischer, C, Gwinn, K & Kang, UJ 2017, 'Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features', Movement Disorders. https://doi.org/10.1002/mds.27232
Goldman, Jennifer G. ; Andrews, Howard ; Amara, Amy ; Naito, Anna ; Alcalay, Roy N. ; Shaw, Leslie M. ; Taylor, Peggy ; Xie, Tao ; Tuite, Paul ; Henchcliffe, Claire ; Hogarth, Penelope (Penny) ; Frank, Samuel ; Saint-Hilaire, Marie Helene ; Frasier, Mark ; Arnedo, Vanessa ; Reimer, Alyssa N. ; Sutherland, Margaret ; Swanson-Fischer, Christine ; Gwinn, Katrina ; Kang, Un Jung. / Cerebrospinal fluid, plasma, and saliva in the BioFIND study : Relationships among biomarkers and Parkinson's disease Features. In: Movement Disorders. 2017.
@article{3ddf80e44b324b50bb907750ab51b878,
title = "Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features",
abstract = "Objective: Examine relationships among neurodegenerative biomarkers and PD motor and nonmotor symptoms. Background: CSF alpha-synuclein is decreased in PD versus healthy controls, but whether plasma and saliva alpha-synuclein differentiate these groups is controversial. Correlations of alpha-synuclein among biofluids (CSF, plasma, saliva) or biomarkers (eg, beta-amyloid, tau [total, phosphorylated]) are not fully understood. The relationships of these biomarkers with PD clinical features remain unclear. Methods: BioFIND, a cross-sectional, observational study, examines clinical and biomarker characteristics in moderate-advanced PD and matched healthy controls. We compared alpha-synuclein concentrations across diagnosis, biofluids, and CSF biomarkers. Correlations of CSF biomarkers and MDS-UPDRS, motor phenotype, MoCA, and rapid eye movement sleep behavior disorder questionnaire scores in PD were examined. Results: CSF alpha-synuclein was lower in PD versus controls (P=.01), controlling for age, gender, and education. Plasma and saliva alpha-synuclein did not differ between PD and controls, and alpha-synuclein did not significantly correlate among biofluids. CSF beta-amyloid1-42 was lower in PD versus controls (P<.01), and correlated weakly with MoCA recall scores (r=0.23, P=.02). CSF alpha-synuclein was lower in the postural instability/gait difficulty phenotype than other motor phenotypes (P<.01). No CSF biomarkers predicted or correlated with total motor or rapid eye movement sleep behavior disorder scores. CSF alpha-synuclein correlated with beta-amyloid1-42, total-tau, and phosphorylated-tau (r=0.41, 0.81, 0.43, respectively; Ps<.001). Conclusion: Lower CSF alpha-synuclein is associated with diagnosis and motor phenotype in moderate-advanced PD. Plasma and saliva alpha-synuclein neither correlate with CSF alpha-synuclein, nor distinguish PD from controls. CSF beta-amyloid1-42 remains a potential biomarker for cognitive impairment in PD.",
keywords = "Alpha-synuclein, Amyloid, Cerebrospinal fluid, Postural instability gait difficulty, Tau",
author = "Goldman, {Jennifer G.} and Howard Andrews and Amy Amara and Anna Naito and Alcalay, {Roy N.} and Shaw, {Leslie M.} and Peggy Taylor and Tao Xie and Paul Tuite and Claire Henchcliffe and Hogarth, {Penelope (Penny)} and Samuel Frank and Saint-Hilaire, {Marie Helene} and Mark Frasier and Vanessa Arnedo and Reimer, {Alyssa N.} and Margaret Sutherland and Christine Swanson-Fischer and Katrina Gwinn and Kang, {Un Jung}",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/mds.27232",
language = "English (US)",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Cerebrospinal fluid, plasma, and saliva in the BioFIND study

T2 - Relationships among biomarkers and Parkinson's disease Features

AU - Goldman, Jennifer G.

AU - Andrews, Howard

AU - Amara, Amy

AU - Naito, Anna

AU - Alcalay, Roy N.

AU - Shaw, Leslie M.

AU - Taylor, Peggy

AU - Xie, Tao

AU - Tuite, Paul

AU - Henchcliffe, Claire

AU - Hogarth, Penelope (Penny)

AU - Frank, Samuel

AU - Saint-Hilaire, Marie Helene

AU - Frasier, Mark

AU - Arnedo, Vanessa

AU - Reimer, Alyssa N.

AU - Sutherland, Margaret

AU - Swanson-Fischer, Christine

AU - Gwinn, Katrina

AU - Kang, Un Jung

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: Examine relationships among neurodegenerative biomarkers and PD motor and nonmotor symptoms. Background: CSF alpha-synuclein is decreased in PD versus healthy controls, but whether plasma and saliva alpha-synuclein differentiate these groups is controversial. Correlations of alpha-synuclein among biofluids (CSF, plasma, saliva) or biomarkers (eg, beta-amyloid, tau [total, phosphorylated]) are not fully understood. The relationships of these biomarkers with PD clinical features remain unclear. Methods: BioFIND, a cross-sectional, observational study, examines clinical and biomarker characteristics in moderate-advanced PD and matched healthy controls. We compared alpha-synuclein concentrations across diagnosis, biofluids, and CSF biomarkers. Correlations of CSF biomarkers and MDS-UPDRS, motor phenotype, MoCA, and rapid eye movement sleep behavior disorder questionnaire scores in PD were examined. Results: CSF alpha-synuclein was lower in PD versus controls (P=.01), controlling for age, gender, and education. Plasma and saliva alpha-synuclein did not differ between PD and controls, and alpha-synuclein did not significantly correlate among biofluids. CSF beta-amyloid1-42 was lower in PD versus controls (P<.01), and correlated weakly with MoCA recall scores (r=0.23, P=.02). CSF alpha-synuclein was lower in the postural instability/gait difficulty phenotype than other motor phenotypes (P<.01). No CSF biomarkers predicted or correlated with total motor or rapid eye movement sleep behavior disorder scores. CSF alpha-synuclein correlated with beta-amyloid1-42, total-tau, and phosphorylated-tau (r=0.41, 0.81, 0.43, respectively; Ps<.001). Conclusion: Lower CSF alpha-synuclein is associated with diagnosis and motor phenotype in moderate-advanced PD. Plasma and saliva alpha-synuclein neither correlate with CSF alpha-synuclein, nor distinguish PD from controls. CSF beta-amyloid1-42 remains a potential biomarker for cognitive impairment in PD.

AB - Objective: Examine relationships among neurodegenerative biomarkers and PD motor and nonmotor symptoms. Background: CSF alpha-synuclein is decreased in PD versus healthy controls, but whether plasma and saliva alpha-synuclein differentiate these groups is controversial. Correlations of alpha-synuclein among biofluids (CSF, plasma, saliva) or biomarkers (eg, beta-amyloid, tau [total, phosphorylated]) are not fully understood. The relationships of these biomarkers with PD clinical features remain unclear. Methods: BioFIND, a cross-sectional, observational study, examines clinical and biomarker characteristics in moderate-advanced PD and matched healthy controls. We compared alpha-synuclein concentrations across diagnosis, biofluids, and CSF biomarkers. Correlations of CSF biomarkers and MDS-UPDRS, motor phenotype, MoCA, and rapid eye movement sleep behavior disorder questionnaire scores in PD were examined. Results: CSF alpha-synuclein was lower in PD versus controls (P=.01), controlling for age, gender, and education. Plasma and saliva alpha-synuclein did not differ between PD and controls, and alpha-synuclein did not significantly correlate among biofluids. CSF beta-amyloid1-42 was lower in PD versus controls (P<.01), and correlated weakly with MoCA recall scores (r=0.23, P=.02). CSF alpha-synuclein was lower in the postural instability/gait difficulty phenotype than other motor phenotypes (P<.01). No CSF biomarkers predicted or correlated with total motor or rapid eye movement sleep behavior disorder scores. CSF alpha-synuclein correlated with beta-amyloid1-42, total-tau, and phosphorylated-tau (r=0.41, 0.81, 0.43, respectively; Ps<.001). Conclusion: Lower CSF alpha-synuclein is associated with diagnosis and motor phenotype in moderate-advanced PD. Plasma and saliva alpha-synuclein neither correlate with CSF alpha-synuclein, nor distinguish PD from controls. CSF beta-amyloid1-42 remains a potential biomarker for cognitive impairment in PD.

KW - Alpha-synuclein

KW - Amyloid

KW - Cerebrospinal fluid

KW - Postural instability gait difficulty

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=85038265593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038265593&partnerID=8YFLogxK

U2 - 10.1002/mds.27232

DO - 10.1002/mds.27232

M3 - Article

C2 - 29205509

AN - SCOPUS:85038265593

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

ER -